Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia

Br J Haematol. 2018 Feb;180(3):448-451. doi: 10.1111/bjh.14340. Epub 2016 Sep 21.
No abstract available

Keywords: CBFB-MYH11; acute myeloid leukaemia; allogeneic haematopoietic cell transplantation; minimal residual disease.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia, Myeloid, Acute / diagnosis*
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / therapy
  • Male
  • Middle Aged
  • Mutation*
  • Neoplasm, Residual / diagnosis*
  • Oncogene Proteins, Fusion / genetics*
  • Prognosis
  • Proto-Oncogene Proteins c-kit / genetics*
  • Recurrence
  • Transplantation, Homologous
  • Young Adult

Substances

  • CBFbeta-MYH11 fusion protein
  • Oncogene Proteins, Fusion
  • inv(16) fusion protein, human
  • Proto-Oncogene Proteins c-kit